Y-90 and immunotherapy vs Y-90 plus placebo for liver cancer
Part of Cancer, Digestive system clinical trials.
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a clear diagnosis of liver cancer (HCC), confirmed by scan criteria or biopsy
- Your cancer is locally advanced but has no spread outside the liver
- You must be eligible for Y-90 treatment based on a special scan (MAA with lung safety limits)
- You have not had liver radiation before, and you have not had prior drug treatment for HCC (systemic therapy)
- Your liver function is strong enough for study treatment (Child-Pugh A) and blood counts meet thresholds
- You must have recent endoscopy treatment of any stomach/esophagus vein swelling (varices) before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This study compares two liver-directed treatments—radioactive Yttrium-90 beads (SIRT) and a type of chemo infusion directly into the liver (HAIC)—for people whose liver cancer is advanced enough to need treatment but might still be removable with surgery. The goal is to see which approach can shrink the tumor best before surgery.
This trial studies whether combining three treatments—an immunotherapy drug (Atezo), a blood-vessel-blocking drug (Bev), and a radioactive bead treatment (SIRT-Y90)—can help patients with advanced liver cancer that cannot be surgically removed. The goal is to see if using all three together works better than using fewer treatments.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.